Faster cognitive decline was seen for older adults with both conditions.
COVID-19 linked to increased risk of neurological disorders
Jun 30, 2022
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
Alzheimer’s disease in Down syndrome similar to autosomal dominant form
May 25, 2022
Age at onset and mortality for Alzheimer’s disease in people with Down syndrome were comparable with fully penetrant form of the disease.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.
Donanemab slows clinical progression in early Alzheimer’s disease
Jul 17, 2023
The drug slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
17 percent of patients seeing neurologist travel long distance
Sep 13, 2023
Factors associated with long-distance travel include low neurologist density, rural setting and visits for ALS and nervous system cancer.
Strategies needed to improve delivery of Alzheimer’s disease-modifying therapies
Jan 30, 2024
Models that enable primary care practitioners to diagnose disease and evaluate patients for treatment eligibility would have biggest effect on wait times, the study found.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.